STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology

XTL Biopharmaceuticals Makes Bold Bet on Autism Breakthrough with NeuroNOS Acquisition

byLiliana Vida
January 13, 2026
in Biotechnology, Small-Cap
Reading Time: 2 mins read
Share on TwitterShare on LinkedIn

Transformative deal targets the biological roots of autism, opening a new frontier in disease-modifying therapy.

XTL Biopharmaceuticals has taken a decisive step into one of the most urgent and underserved areas of modern medicine by signing a binding agreement to acquire 85% of NeuroNOS Ltd., a biotechnology company focused on disease-modifying treatments for Autism Spectrum Disorder (ASD) and neuro-oncology. The transaction, announced in January, positions XTL at the forefront of a rapidly expanding autism therapeutics market, where no approved therapies currently address the biological drivers of the condition.

Unlike existing treatments that focus only on managing behavioral symptoms, NeuroNOS is developing therapies designed to target the core molecular and neurological mechanisms underlying autism. This approach aims to modify the disease itself, rather than simply mitigating its outward effects, offering the possibility of fundamentally changing outcomes for patients and families.

Beyond Air, NeuroNOS’s parent company, will retain a 19.99% ownership stake in XTL following the transaction and is eligible to receive up to $32.5 million in upfront, development, and commercial milestone payments. The structure reflects both companies’ confidence in the long-term value of NeuroNOS’s platform while aligning incentives for clinical and commercial success.

The timing of the acquisition is notable. Autism now affects approximately one in 31 children in the United States, a staggering increase that has placed immense pressure on healthcare systems, schools, and families. Despite decades of research, no FDA-approved therapies currently exist to alter the biological course of autism, leaving a massive unmet medical need.

Public policy attention is also intensifying. Recent statements from U.S. leadership have underscored autism as a growing public health crisis, increasing the likelihood of regulatory, funding, and research support for innovative solutions.

By acquiring NeuroNOS, XTL is not simply expanding its pipeline — it is entering a market with profound social, medical, and economic impact. If NeuroNOS’s science delivers on its promise, the company could help redefine how autism is treated, moving the field beyond symptom management toward true disease modification.

You might like this article:Google Joins the $4 Trillion Club as AI Boom Rewrites Big Tech’s Power Rankings

Tags: GrowthMoversNewsStock MarketXAIR
Previous Post

Google Joins the $4 Trillion Club as AI Boom Rewrites Big Tech’s Power Rankings

Next Post

KULR Secures $30 Million Battery Supply Deal, Accelerating U.S. Energy Storage Expansion

Related Posts

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

byLiliana Vida
November 18, 2026
0

New KULR ONE Max order strengthens the company's energy storage portfolio, with deliveries scheduled through 2027. KULR Technology Group (NYSE:...

chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

byLiliana Vida
November 17, 2026
0

Pivotal REGAL trial demonstrates significant survival benefits, positioning the company for a potential FDA submission in 2027. SELLAS Life Sciences...

KULR Technology Revenue Surges 197% in Q3 as Battery Sales Nearly Quadruple

byLuca Blaumann
November 10, 2026
0

Company reports $7.4 million in quarterly revenue, exits Bitcoin holdings, and strengthens its balance sheet with $54.5 million in cash...

Next Post

KULR Secures $30 Million Battery Supply Deal, Accelerating U.S. Energy Storage Expansion

Latest News

Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

Based on Your Interest

Artificial Intelligence

CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

November 11, 2026
Artificial Intelligence

CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results

November 10, 2026
investing
Artificial Intelligence

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

November 10, 2026

Recommended

Auto Manufacturers

Lucid Secures $1.75 Billion Liquidity Boost From Saudi PIF to Support Turnaround

November 10, 2026
Artificial Intelligence

KULR Technology Revenue Surges 197% in Q3 as Battery Sales Nearly Quadruple

November 10, 2026
Aerospace & Defense

Rocket Lab Q3 Revenue Surges 73% to $268 Million, Beating Wall Street Expectations

November 9, 2026
Artificial Intelligence

IonQ Shares Climb as Company Expands Government Reach Through Carahsoft Partnership

November 9, 2026
Aerospace & Defense

AST SpaceMobile and Rakuten Launch Joint Venture Backed by $1 Billion in Japanese Government Funding

November 9, 2026
Stoxpo

Follow us on social media:

Highlights

  • Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders
  • KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems
  • SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results
  • Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers
  • D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders

November 20, 2026

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

November 18, 2026
chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

November 17, 2026
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.